Edwards Lifesciences (EW) Stock Price
Edwards Lifesciences Price
Revenue has compounded at 9.7% per year over the past 19 years to 6.07 B USD. Earnings per share have grown at 12.8% per year over the last 19 years. Edwards Lifesciences's net margin stands at 17.7%, down from 28.7% several years earlier. Analysts set a median price target of 101.00 USD, implying 12.5% above the current price. Of 38 analysts, 31 rate the stock a buy — an overall Buy consensus.
Edwards Lifesciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Edwards Lifesciences business model & stock analysis
Frequently asked questions about Edwards Lifesciences
The business model of Edwards Lifesciences Corp revolves around the development, manufacturing, and marketing of innovative heart valve treatment solutions. Edwards Lifesciences Corp specializes in transcatheter heart valves and critical care technologies, enabling minimally invasive procedures for treating structural heart disease. The company's products aim to improve patient outcomes and enhance healthcare efficiency. Edwards Lifesciences Corp's business model is driven by its commitment to research and development, strategic collaborations, global expansion, and delivering exceptional quality and value to healthcare providers. Edwards Lifesciences Corp consistently strives to meet the evolving needs of patients worldwide through its innovative solutions in the field of cardiovascular disease management.
Edwards Lifesciences Corp is primarily active in the healthcare industry, specifically in the field of medical devices. The company specializes in the development and manufacturing of innovative heart valves, monitoring systems, and critical care technologies. With a strong focus on cardiovascular diseases, Edwards Lifesciences Corp offers solutions that improve patient outcomes and quality of life. Leveraging their expertise and cutting-edge technology, the company continues to make significant contributions to the medical industry, addressing the growing need for advanced cardiovascular treatments and therapies.
The main competitors of Edwards Lifesciences Corp in the market include Medtronic, Boston Scientific, and Abbott Laboratories. These companies also operate in the medical devices and equipment industry, offering various products and services related to cardiovascular healthcare. Edwards Lifesciences Corp, a leading player in this sector, faces intense competition from these firms in areas such as heart valve replacement, monitoring systems, and other innovative technologies. However, Edwards Lifesciences Corp has maintained a strong market presence and gained a competitive edge through its exceptional products, continuous advancements, and significant customer trust.
Edwards Lifesciences Corp is a medical technology company founded in 1958. It specializes in developing and manufacturing products for patients with cardiovascular disease. With its headquarters in Irvine, California, Edwards Lifesciences Corp has grown to become a leading global player in the healthcare industry. The company is renowned for its innovative heart valves and hemodynamic monitoring systems, which help improve the lives of patients suffering from heart conditions. Edwards Lifesciences Corp has a rich history of pioneering breakthroughs in heart surgery, making it a trusted name in the field of cardiac care.
Some significant milestones achieved by Edwards Lifesciences Corp include the introduction of the first commercially available artificial heart valve in 1960, the development of the first transcatheter aortic valve system known as SAPIEN in 2002, and the successful launch of the SAPIEN 3 Ultra system in 2015, which showcased improved patient outcomes. Edwards Lifesciences Corp has also achieved regulatory approvals and expanded its product portfolio, providing innovation in heart valve therapy. The company continues to make advancements in medical technology, contributing to improved patient care and enhancing its position in the medical device industry.
Edwards Lifesciences Corp is primarily present in various countries and regions worldwide. The company has a global presence, with a strong focus on North America, Europe, and the Asia-Pacific region. Their innovative medical technologies for cardiovascular disease management and critical care solutions are utilized by healthcare professionals in hospitals and medical centers across the United States, Canada, Germany, France, the United Kingdom, Japan, China, India, and many other countries. Edwards Lifesciences Corp's commitment to advancing patient care extends to various markets, ultimately benefiting individuals and healthcare systems globally.
Edwards Lifesciences Corp represents values of innovation, patient focus, and global collaboration. The company's corporate philosophy revolves around improving patient lives through its life-saving technologies and innovative medical solutions. Edwards Lifesciences Corp is committed to delivering high-quality, accessible, and cost-effective healthcare solutions worldwide. With a strong emphasis on research and development, the company aims to pioneer breakthrough technologies in heart valve therapies and critical care monitoring. Edwards Lifesciences Corp's dedication to improving patient outcomes, advancing medical science, and enhancing the quality of life sets it apart as a renowned leader in the healthcare industry.
Analysts currently set an average price target of 101.70 USD for the Edwards Lifesciences stock (median: 101.00 USD), implying +12.0 % versus the latest price. The consensus is based on 38 analyst ratings.
38 analysts currently rate the Edwards Lifesciences stock: 31 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Edwards Lifesciences to generate revenue of 6.77 B USD and earnings per share of 3.02 USD.
Converted at the current exchange rate, the Edwards Lifesciences share trades at 80.55 EUR (89.75 USD).
The Edwards Lifesciences share (EW) is listed on 9 stock exchanges, including: NYSE (EW), London (0REN.L), SIX (Zürich) (EW.SW), XETRA (EWL.DE), Frankfurt (EWL.F), München (EWL.MU), Düsseldorf (EWL.DU), Wien (EWLS.VI).
Edward Lifesciences Corp is a multinational company that has been developing and producing innovative medical products for heart and vascular diseases for over 60 years. With headquarters in California, USA, the company operates worldwide and employs over 14,000 employees. Edward Lifesciences Corp is a market leader in heart valve and heart monitoring equipment. The company's business model focuses on three main areas: heart valves, hemodynamics, and critical care. In the field of heart valves, the company develops a wide range of products such as biological aortic valves, mechanical aortic valves, transcatheter aortic valve implants (TAVI), mitral valves, and pulmonary valves. These products are used to treat patients with a variety of heart diseases and are known for their high precision, safety, and effectiveness. In the field of hemodynamics, Edward Lifesciences Corp offers products such as catheters, sensors, and monitoring devices for hospitals and clinics. These products help doctors and medical staff to accurately monitor the hemodynamics of patients, especially in the intensive care unit, and to respond quickly and precisely. The critical care division of Edward Lifesciences Corp provides medical devices for monitoring and supporting patients in the intensive care unit. These products include ventilators, blood gas analyzers, and monitoring devices for vital signs. Edward Lifesciences Corp is globally recognized for its research and development and its commitment to the highest standards in medicine. In 1958, Miles "Lowell" Edwards, the founder of the company, invented the first artificial heart valve. Since then, Edward Lifesciences Corp has introduced a variety of innovative products to the market and continues to work on improving the lives of heart patients worldwide. The company is also known for its ability to incorporate the latest technologies into its products. For example, TAVI implants were developed based on the latest innovations in minimally invasive surgery. With the use of state-of-the-art technology and intensive research, the company has established itself as a leading provider of medical devices. Edward Lifesciences Corp is continuously working to improve its business model and incorporate new products and services into its portfolio. The company is not only a leader in research and development but also in the production, marketing, and distribution of its products. Edward Lifesciences Corp is committed to always offering innovative and effective solutions for patients with heart diseases in order to improve their quality of life.
The expected revenue of Edwards Lifesciences is 6.77 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Edwards Lifesciences is 1.76 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Edwards Lifesciences is currently 29.73. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Edwards Lifesciences stock.
The price-to-sales ratio (P/S) of Edwards Lifesciences is currently 7.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Edwards Lifesciences stock.
The Eulerpool Quality Score for Edwards Lifesciences is 6/10.
The ISIN of Edwards Lifesciences is US28176E1082. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Edwards Lifesciences is 936853. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Edwards Lifesciences is EW. The ticker symbol is used to trade Edwards Lifesciences shares on the stock exchange.
Edwards Lifesciences stock
Edwards Lifesciences Peer Group
Edwards Lifesciences Ticker
Edwards Lifesciences FIGI
All fundamentals and in-depth analysis of Edwards Lifesciences
Our stock analysis for Edwards Lifesciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Edwards Lifesciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.